The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer.

Transl Lung Cancer Res · 2021 · PMC8264325 · PMID 34295660

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A meta-analysis, including several studies showing contradictory results on survival, indicated that PD-L1 expression showed a trend towards longer OS in SCLC patients ( 19 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.